Interleukin-15 (IL-15) is a cytokine important for both innate and adaptive immune systems. IL-15 has potential for use in vaccines, cancer therapy, infectious disease, autoimmune disease, and as a vaccine adjuvant.
NCI inventors previously disclosed optimized sequences of heterodimeric IL-15 (hetIL-15), the IL-15 and IL-15 receptor alpha (IL-15Ra) heterodimer. Recently, specific methods, drug schedules and dosage of hetIL-15 have been identified, able to induce entry of lymphocytes into tumors and germinal centers which are classically difficult for drug entry. The regimens described have reduced toxicity and increased entry into germinal centers for HIV infection.
The NCI researchers have also studied a combination of hetIL-15 with a therapeutic HIV vaccine incorporating conserved elements of Gag. This combination effectively induces an immune response and maximizes the entry of immune cells into viral sanctuary sites such as germinal centers. This combination has potential for the treatment of HIV by effectively eliminating infected cells.
• Therapeutic regimens for the treatment of HIV or cancer
• Combination therapy for the treatment of HIV
• Allows lymphocytes to enter viral sanctuary sites such as germinal centers that are not well accessed by other HIV therapies
Pavlakis GN, et al. Heterodimeric IL-15 Induces Effector Cell Activation and Trafficking to the Germinal Centers of SIV Infected Macaques. [Abstract Number OA4-1]
- U.S. Provisional: U.S. Provisional Patent Application Number 62/326,223 , Filed 14 Jul 2016